# Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/targeting-of-the-her2-her3-signaling-axis-overcomes-ligand-mediated-resistance/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Satomi Watanabe,Kimio Yonesaka,Junko Tanizaki,Yoshikane Nonagase,Naoki Takegawa,Koji Haratani,Hisato Kawakami,Hidetoshi Hayashi,Masayuki Takeda,Junji Tsurutani,Kazuhiko Nakagawa |
| Citations | 75 |
| DOI | 10.1002/cam4.1995 |
| Fields | Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cam4.1995 |
| OpenAlex ID | https://openalex.org/W2914195240 |
| PMID | 30701699 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Satomi Watanabe](https://scholariq.org/researchers/satomi-watanabe/)

## Paper journal

- [Cancer Medicine](https://scholariq.org/journals/cancer-medicine/)

## Paper primary topic

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Paper topics

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.